Download App

Log in to access Online Inquiry
Company Overview More
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio’s Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
CEO: Henry M.B.A., Christian O.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

PACB Pacific Biosciences of California
5.600+0.380+7.28%
Pre Mkt Price
5.770+0.17+3.03%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
-17.02% 962.78M 227.59% 1.04B 227.59% 1.04B 417.81% 1.08B
-Cash and cash equivalents
-54.04% 428.57M 464.54% 460.73M -- -- 516.25% 425.39M
-Short-term investments
134.38% 534.2M 146.07% 583.68M -- -- 369.1% 654.5M
Receivables
115.81% 27.85M 43.97% 24.24M 43.97% 24.24M 102.83% 23.95M
-Accounts receivable
115.81% 27.85M 43.97% 24.24M 43.97% 24.24M 102.83% 23.95M
Inventory
82.11% 29.63M 72.87% 24.6M 72.87% 24.6M 14.65% 18.28M
Prepaid assets
50.03% 8.44M 51.83% 7.39M 51.83% 7.39M 123.94% 7.19M
Restricted cash
-40.19% 500K -40.19% 500K -- 5.09M -- 500K
Total current assets
-13.94% 1.03B 209.67% 1.1B 211.69% 1.11B 371.72% 1.13B
Non current assets
Net PPE
50.71% 80.43M 44.25% 79.12M 44.25% 79.12M 34.42% 76.98M
-Gross PPE
50.71% 80.43M 29.28% 135.41M 44.25% 79.12M 34.42% 76.98M
-Accumulated depreciation
-- -- -12.82% -56.29M -- -- -- --
Goodwill and other intangible assets
-- 820.73M -- 820.95M -- 820.95M -- 822.74M
-Goodwill
-- 409.97M -- 409.97M -- 409.97M -- 411.53M
-Other intangible assets
-- 410.75M -- 410.98M -- 410.98M -- 411.21M
Other non current assets
77.24% 6.32M 62.63% 5.76M -73.28% 1.17M 30.72% 4.63M
Total non current assets
1493.86% 907.48M 1451.27% 905.84M 1421.63% 901.24M 1387.17% 904.35M
Total assets
54.58% 1.94B 384.8% 2.01B 384.8% 2.01B 577.33% 2.03B
Liabilities
Current liabilities
Payables
407.26% 17.61M 207.4% 11M 207.4% 11M -8.25% 4.96M
-accounts payable
407.26% 17.61M 207.4% 11M 207.4% 11M -8.25% 4.96M
Current accrued expenses
32.83% 19.49M 109% 36.26M 109% 36.26M 104.39% 30.82M
Current debt and capital lease obligation
81.12% 8.06M 77.98% 7.71M -- -- 69.03% 7.13M
-Current capital lease obligation
81.12% 8.06M 77.98% 7.71M -- -- 69.03% 7.13M
Current deferred liabilities
32.5% 12.73M 25.85% 10.98M 250.11% 36.03M -90.69% 9.77M
Other current liabilities
103.31% 3.13M -12.93% 2.16M -- -- 401.2% 2.93M
Current liabilities
80.84% 61.01M 86.25% 71.71M 128.25% 83.29M -57.31% 55.61M
Non current liabilities
Long term debt and capital lease obligation
1.27% 943.96M 2411.58% 946.04M 2170.88% 953.75M 2338.25% 945.87M
-Long term debt
0.06% 896.22M -- 896.07M -- 896.07M -- 895.92M
-Long term capital lease obligation
30.85% 47.74M 32.66% 49.97M 37.34% 57.68M 28.77% 49.95M
Non current deferred liabilities
343.92% 25.25M 1497.51% 25.05M -- -- 947.53% 18.45M
Other non current liabilities
22755.32% 171.87M 22930.32% 173.19M -- 178.95M -- 173.42M
Total non current liabilities
21.57% 1.14B 2761.62% 1.14B 2596.95% 1.13B 2705.49% 1.14B
Total liabilities
23.63% 1.2B 1449.24% 1.22B 1449.24% 1.22B 598.59% 1.19B
Shareholders'equity
Share capital
13.13% 224K 15.1% 221K -- -- 22.78% 221K
-common stock
13.13% 224K 15.1% 221K -- -- 22.78% 221K
-Preferred stock
-- 0 -- 0 -- -- -- 0
Retained earnings
-15.59% -1.3B -17.48% -1.22B -- -- -3.32% -1.15B
Paid-in capital
45.1% 2.04B 46.49% 2.01B -- -- 60.3% 1.99B
Gains losses not affecting retained earnings
-5620.27% -4.09M -1378.82% -1.09M -- -- -77.12% 27K
Total stockholders'equity
161.83% 734.58M 135.77% 790.99M 135.77% 790.99M 549.29% 840.81M
Total equity
161.83% 734.58M 135.77% 790.99M 135.77% 790.99M 549.29% 840.81M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%